Section one: Contracting authority
one.1) Name and addresses
THE UNIVERSITY OF BIRMINGHAM
Edgbaston
BIRMINGHAM
B152TT
Contact
Kseniya Samsonik
Country
United Kingdom
Region code
UKG31 - Birmingham
Companies House
RC000645
Internet address(es)
Main address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Education
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Tender for the Supply of Services - Independent Central Review Of Primary Outcome Data For The GLO-BHNL Platform Clinical Trial - University Of Birmingham
Reference number
SC12106/23
two.1.2) Main CPV code
- 85150000 - Medical imaging services
two.1.3) Type of contract
Services
two.1.4) Short description
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
two.1.5) Estimated total value
Value excluding VAT: £5,000,000
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKG3 - West Midlands
two.2.4) Description of the procurement
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
two.2.5) Award criteria
Quality criterion - Name: Compliance to the Specifications / Weighting: 45
Quality criterion - Name: After Sales and Technical back up / Weighting: 15
Quality criterion - Name: Delivery and Training / Weighting: 15
Quality criterion - Name: Sustainability and Environmental / Weighting: 10
Quality criterion - Name: Standard Supplier Questionnaire (SQ) Part 1 and Part 2 / Weighting: 10
Price - Weighting: 5
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
30 March 2024
End date
30 March 2031
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
15 December 2023
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.7) Conditions for opening of tenders
Date
15 December 2023
Local time
12:01pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
University of Birmingham
Birmingham
Country
United Kingdom